Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen
- PMID: 19098844
- DOI: 10.1038/ajg.2008.87
Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen
Abstract
Objectives: The European Helicobacter Study Group has recently issued the current concepts in the management of Helicobacter pylori infection (Maastricht III Consensus Report, 2005). The aim of the study was to examine the cumulative H. pylori eradication rates that can be achieved in clinical practice by adopting first and second regimens as proposed by the Maastricht III consensus and a third-line empirical levofloxacin-based regimen.
Methods: H. pylori-positive patients were treated initially with a first-line eradication triple regimen consisting of omeprazole, amoxicillin, and clarithromycin and subsequently with a second-line quadruple regimen consisting of omeprazole, bismuth, metronidazole, and tetracycline. Finally, after two previous H. pylori eradication failures, patients received omeprazole, amoxicillin, and levofloxacin, as a third-line empirical strategy. The success rate was calculated by both intention-to-treat (ITT) and per protocol (PP) analyses.
Results: In total, 540 consecutive H. pylori-positive patients received first-line treatment (omeprazole, amoxicillin, and clarithromycin). H. pylori were eradicated in 380 patients and 40 patients were withdrawn (ITT, 70.3%; PP, 76%). The remaining 120 H. pylori-positive patients received second-line treatment (omeprazole, bismuth, metronidazole, and tetracycline). H. pylori were eradicated in 83 patients and 7 patients were withdrawn (ITT, 69.1%; PP, 73.45%). Finally, the remaining 30 H. pylori-positive patients received third-line treatment (omeprazole, amoxicillin, and levofloxacin). H. pylori were eradicated in 21 patients and 0 patients were withdrawn (ITT, 70%; PP, 70%). Thus, out of 540 patients initially included in the study, H. pylori were eradicated in 484 patients, 47 were withdrawn, and only 9 remained positive. These results give 89.6% ITT and 98.1% PP cumulative H. pylori eradication rates.
Conclusions: By adopting first- and second-line regimens, as proposed by the Maastricht III consensus and a third-line levofloxacin-based empirical regimen, high cumulative H. pylori eradication rates can be achieved. Thus, a substantial number of cultures to determine sensitivity to antibiotics can be avoided with beneficial consequences concerning cost.
Similar articles
-
High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.Helicobacter. 2010 Jun;15(3):233-8. doi: 10.1111/j.1523-5378.2010.00758.x. Helicobacter. 2010. PMID: 20557366 Clinical Trial.
-
Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.J Gastroenterol Hepatol. 2005 Apr;20(4):637-42. doi: 10.1111/j.1440-1746.2005.03801.x. J Gastroenterol Hepatol. 2005. PMID: 15836716 Clinical Trial.
-
The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.J Dig Dis. 2007 Nov;8(4):211-5. doi: 10.1111/j.1751-2980.2007.00308.x. J Dig Dis. 2007. PMID: 17970879 Clinical Trial.
-
'Rescue' therapies for the management of Helicobacter pylori infection.Dig Dis. 2006;24(1-2):113-30. doi: 10.1159/000090315. Dig Dis. 2006. PMID: 16699270 Review.
-
Helicobacter pylori "rescue" therapy after failure of two eradication treatments.Helicobacter. 2005 Oct;10(5):363-72. doi: 10.1111/j.1523-5378.2005.00324.x. Helicobacter. 2005. PMID: 16181345 Review.
Cited by
-
Trends in the eradication rates of Helicobacter pylori infection for eleven years.World J Gastroenterol. 2012 Dec 7;18(45):6628-34. doi: 10.3748/wjg.v18.i45.6628. World J Gastroenterol. 2012. PMID: 23236238 Free PMC article.
-
Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy.Gastroenterol Res Pract. 2012;2012:757926. doi: 10.1155/2012/757926. Epub 2012 Jun 19. Gastroenterol Res Pract. 2012. PMID: 22778723 Free PMC article.
-
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial.J Korean Med Sci. 2011 Jun;26(6):785-90. doi: 10.3346/jkms.2011.26.6.785. Epub 2011 May 18. J Korean Med Sci. 2011. PMID: 21655065 Free PMC article. Clinical Trial.
-
Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: a randomized clinical trial.Can J Gastroenterol. 2011 Apr;25(4):207-13. doi: 10.1155/2011/672093. Can J Gastroenterol. 2011. PMID: 21523262 Free PMC article. Clinical Trial.
-
Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan.J Gastroenterol. 2013 Oct;48(10):1128-35. doi: 10.1007/s00535-012-0731-8. Epub 2013 Jan 11. J Gastroenterol. 2013. PMID: 23307042 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous